Perrigo Company Company Profile (NYSE:PRGO)

Perrigo Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

Perrigo Company declared a quarterly dividend on Tuesday, August 8th. Shareholders of record on Friday, August 25th will be paid a dividend of $0.16 per share on Tuesday, September 12th. This represents a $0.64 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend is Wednesday, August 23rd. View Perrigo Company's Dividend History.

Perrigo Company (NYSE:PRGO) issued its quarterly earnings data on Thursday, August, 10th. The company reported $1.22 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.94 by $0.28. The company earned $1.24 billion during the quarter, compared to analysts' expectations of $1.18 billion. Perrigo Company had a positive return on equity of 11.55% and a negative net margin of 51.04%. The company's quarterly revenue was down 7.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.93 earnings per share. View Perrigo Company's Earnings History.

Perrigo Company is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Perrigo Company.

Perrigo Company updated its FY17 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of $4.45-4.70 for the period, compared to the Thomson Reuters consensus estimate of $4.28.

15 brokers have issued twelve-month price objectives for Perrigo Company's shares. Their predictions range from $64.00 to $125.00. On average, they expect Perrigo Company's stock price to reach $87.77 in the next year. View Analyst Ratings for Perrigo Company.

Here are some recent quotes from research analysts about Perrigo Company stock:

• 1. Canaccord Genuity analysts commented, "Date and time of first dissemination: May 22, 2017, 23:13 ET Date and time of production: May 22, 2017, 22:26 ET Target Price / Valuation Methodology: Perrigo Company – PRGO Discounted cash flow analysis supports an $86 valuation for PRGO shares Our discounted cash flow (DCF) analysis leads us to a price target of $86/share for PRGO. Our DCF considers our estimates through 2021, low-single-digit growth through 2033 and zero terminal growth thereafter. In addition, we expect Perrigo’s margin structure to remain somewhat consistent with our 2021 estimates." (5/22/2017)
• 2. Deutsche Bank AG analysts commented, "We updated our model to reflect PRGO's divestiture of the Tysabri royalty stream to Royalty Pharma, which the company expects to complete this month, and preliminary assumptions for de-leveraging with the proceeds. The net effect of these changes was EPS dilution of ~15-20% over 2017-21 and a reduction in our DCF-derived PT to $87 (from $93), as our prior model reflected more value for the Tysabri royalty stream (~$3bn) relative to the upfront payment of $2.2bn. We have not factored in the potential sales-based milestone payments of $650mn, which could add ~$4/share to the theoretical DCF value if they hit. We continue to view PRGO as a unique asset with good value creation potential over the longer term, and are maintaining our Buy rating. Solid execution in the coming quarters will be critical for the stock, in our view." (3/14/2017)
• 3. Jefferies Group LLC analysts commented, "Unaudited Q4 results were ahead of forecast. But the real story is FY17 guidance and it disappointed even after sharp cuts to Street models just 4 weeks ago. For the first time we can recall both rev & EPS will decline ' not a good story line for an OTC-focused company. Tysabri's sale helps de-lever PRGO but at the same time shrinks the EPS base by ~$2.20. Mgt continues to make moves to enhance shareholder value ' but it may take quite some time to do so." (2/28/2017)
• 4. Royal Bank Of Canada analysts commented, "While we expected a challenging 2017 guide, it was worse than we anticipated and came with an unexpected CFO departure. The strategic review around whether to sell Rx/generics will linger, limiting visibility but the conundrum is that we do not see upside in either scenario. We remain on the sidelines with target down to $68. Several additional thoughts after speaking with management this evening." (2/28/2017)

Some companies that are related to Perrigo Company include Cerner Corporation (CERN), Zimmer Biomet Holdings (ZBH), Incyte Corporation (INCY), C.R. Bard (BCR), Edwards Lifesciences Corporation (EW), Quintiles Transitional Holdings (Q), Lonza Group Ag (LZAGY), Cardinal Health (CAH), Mylan N.V. (MYL), AmerisourceBergen Corporation (Holding Co) (ABC), Smith & Nephew SNATS (SNN), BioMarin Pharmaceutical (BMRN), Centene Corporation (CNC), Align Technology (ALGN), Laboratory Corporation of America Holdings (LH), Teva Pharmaceutical Industries Limited (TEVA), Eisai Co., Ltd (ESALY) and Grifols, S.A. (GRFS).

Shares of Perrigo Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Perrigo Company stock can currently be purchased for approximately $87.04.